Pompe disease (PD) is a rare, inherited autosomal recessive metabolic disorder caused by the deficiency of the lysosomal acid alpha-glucosidase (GAA) enzyme described in 1932 by the Dutch pathologist Joannes Cassianus Pompe. The prevalence of PD ranges from 1:40,000 to 1:300,000 births and depends on geographic and ethnic factors. Clinical manifestations may vary from a rapidly progressive disabling disease with cardiomegaly, hepatomegaly, weakness, generalized hypotonia, and death within the first year of life, to a mild presentation characterized by slowly progressive myopathy predominantly involving the skeletal muscles. The laboratory diagnostic gold standard is represented by the determination of the alpha-glucosidase activity. However, the muscle histology may also yield the diagnosis by evaluating the tissular glycogen accumulation. Until recently, supportive measures constituted the unique available therapy. Currently, the administration of the recombinant GAA is being used with promising results. The authors present the case of a 5-month-old boy, previously diagnosed with hypertrophic cardiomyopathy since the age of 2 months, who presented acute heart failure accompanied by biventricular dilation followed by refractory shock and death. The autopsy findings confirmed the glycogen-accumulation disease.
Keywords
Autopsy, Glycogen Storage Disease Type II, GAA protein, human, Cardiomyopathy, Diagnosis
References
PryceJW, BamberAR, AshworthMT, KihoL, MaloneM, SebireNJ. Reference ranges for organ weights of infants at autopsy: results of >1,000 consecutive cases from a single centre. BMC Clin Pathol. 2014;14(1):18. [https://doi.org/10.1186/1472-6890-14-18]. [PMID:24822034]
RabenN, RobertsA, PlotzPH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 2007;26(1):45-8. [PMID:17915569]
HagemansMLC, WinkelLPF, Van DoornPA, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671-7. [https://doi.org/10.1093/brain/awh384]. [PMID:15659425]
LewandowskaE, Wierzba-BobrowiczT, RolaR, et al. Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study. Folia Neuropathol. 2008;46(2):123-33. [PMID:18587706]
UmapathysivamK, HopwoodJJ, MeiklePJ. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem. 2001;47(8):1378-83. [PMID:11468225]
AnY, YoungSP, HillmanSL, Van HoveJL, ChenYT, MillingtonDS. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem. 2000;287(1):136-43. [https://doi.org/10.1006/abio.2000.4838]. [PMID:11078593]
Van der KraanM, KroosMA, JoosseM, et al. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun. 1994;203(3):1535-41. [https://doi.org/10.1006/bbrc.1994.2360]. [PMID:7945303]
HirschhornR, HuieML. Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally “common” in White populations. J Med Genet. 1999;36(1):85-6. [PMID:9950376]
SchoserBG, Müller-HöckerJ, HorvathR, et al. Adult-onset glycogen storage disease type 2: clinic-pathological phenotype revisited. Neuropathol Appl Neurobiol. 2007;33(5):544-59. [PMID:17573812]
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email